Adamas Pharmaceuticals, Inc. - Common Stock ADMS releases its next round of earnings Thursday. Get the latest predictions in Benzinga's essential guide to the company's Q4 earnings report.
Earnings and Revenue
Wall Street analysts see Adamas reporting a quarterly loss of $1.18 per share on sales of $840,000.
In the same quarter last year, Adamas announced EPS loss of 68 cents on revenue of $37,000. Here's how the company's reported EPS has stacked up against analyst estimates in the past:
| Quarter | Q3 2017 | Q2 2017 | Q1 2017 | Q4 2016 |
| EPS Estimate | -0.98 | -0.81 | -0.7 | -0.8 |
| EPS Actual | -1.04 | -0.93 | -0.72 | -0.68 |
Stock Performance
Over the last 52-week period, shares are up 52.72 percent. Given that these returns are generally positive, long-term shareholders can be content going into this earnings release.
Analysts have adjusted their estimates lower for EPS and revenues over the past 90 days. The average rating by analysts on Adamas stock is a Neutral. The validity of this rating has maintained conviction over the past 90 days.
Conference Call
Adamas is scheduled to hold a conference call at 4:30 p.m. ET and it can be accessed here: https://edge.media-server.com/m6/p/fybxdpki
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
